Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
WALTHAM, Mass.--(BUSINESS WIRE)--Dec 1, 2022--
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 6, 2022 at 10:40 AM ET.
A live webcast of the fireside chat will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be archived on the Company’s website for 90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
View source version on businesswire.com:https://www.businesswire.com/news/home/20221201005230/en/
CONTACT: Investor Relations:
Maghan Meyers
Argot Partners
Deciphera@argotpartners.com
212-600-1902Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Deciphera Pharmaceuticals, Inc.
Copyright Business Wire 2022.
